TY - JOUR
T1 - Synthesis and tumor-initiating activity in mouse skin of dibenzo[a,l]pyrene syn- and anti-fjord-region diolepoxides
AU - Gill, H. S.
AU - Kole, P. L.
AU - Wiley, J. C.
AU - K.-M. li, li
AU - Higginbotham, S.
AU - Rogan, E. G.
AU - Cavalieri, E. L.
N1 - Funding Information:
The authors thankfully acknowledge the histopathological review of malignant tumors by Dr Sonny LJohansson, the technical assistance of John RJacobsen, and the production and editorial assistance of Joseph H.Saugier and Carol Y.Shaw during the preparation of this manuscript. This work was supported by grant R01-CA49917 (Eppley Institute) and by contract NO 1-CP-15732 (Chemsyn) with the National Cancer Institute. Core support at the Eppley Institute is provided by grant P3O-CA36727.
PY - 1994/11
Y1 - 1994/11
N2 - Dibenzo[a,l]pyrene (DB[a,l]P) is the most potent carcinogen among polycycic aromatic hydrocarbons. Because the fjord-region diolepoxide (DE) pathway is one of the mech anisms of activation, (±)-trans-DB [a,l]P-11,12-dihydrodiol,(±)-anti-DB[a,l]PDE and (±)-syn-DB[a,l]PDE were synthesized. The key intermediate for these syntheses, 12-methoxy-DB[a,l]P, was successfully obtained by cyclizatlon of 6-(3-methoxybenzyl)benzanthrone with methanesulfonic acid, which in turn was prepared by 1,4 conjugate addition of 3-methoxybenzyl magnesium bromide to benzanthrone. The presence of the DB[a,l]P nucleus in the dihydrodiol epoxides and diolepoxides was proven by conversion of 12-methoxyDB[a,l]P into the parent compound in several steps. The tumor-initiating activity of the two diolepoxides in mouse skin was compared to that of DB[a,l]P-11,12-dihydrodiol and the parent DB[a,l]P Groups of 24 8 week old female SENCAR mice were topically initiated with 12, 4 or 133 nmol of compound In 100 μl of acetone. Starting 1 week later, promotion with 12-O-tetradecanoylphorbol-13-acetate (1.62 nmol In 100 μl acetone) was begun and continued twice weekly for 30 weeks. At the 12, 4 and 1.33 nmol doses, anti-DB[a,l]PDE induced 2.0, 0.7 and 0.7 tumors per mouse (t/m) respectively, whereas syn DB[a,l]PDE induced 1.8, 1.5 and 1.8 t/m. At the same three doses, DB[a,l]P-11,12-dihydrodiol induced 4.6, 4.3 and 2.8 t/m, and DB[a,l]P resulted in 9.3,7.1 and 5.2 t/m. These results confirm that DB[a,l]P is more potent than its 11,12-dihydrodlol and show that the two diolepoxides are less tumorlgenic than their precursors. At the medium and low doses, syn-DB[a,l]PDE is more tumorigenic than its congener anti-DB[a,l]PDE.
AB - Dibenzo[a,l]pyrene (DB[a,l]P) is the most potent carcinogen among polycycic aromatic hydrocarbons. Because the fjord-region diolepoxide (DE) pathway is one of the mech anisms of activation, (±)-trans-DB [a,l]P-11,12-dihydrodiol,(±)-anti-DB[a,l]PDE and (±)-syn-DB[a,l]PDE were synthesized. The key intermediate for these syntheses, 12-methoxy-DB[a,l]P, was successfully obtained by cyclizatlon of 6-(3-methoxybenzyl)benzanthrone with methanesulfonic acid, which in turn was prepared by 1,4 conjugate addition of 3-methoxybenzyl magnesium bromide to benzanthrone. The presence of the DB[a,l]P nucleus in the dihydrodiol epoxides and diolepoxides was proven by conversion of 12-methoxyDB[a,l]P into the parent compound in several steps. The tumor-initiating activity of the two diolepoxides in mouse skin was compared to that of DB[a,l]P-11,12-dihydrodiol and the parent DB[a,l]P Groups of 24 8 week old female SENCAR mice were topically initiated with 12, 4 or 133 nmol of compound In 100 μl of acetone. Starting 1 week later, promotion with 12-O-tetradecanoylphorbol-13-acetate (1.62 nmol In 100 μl acetone) was begun and continued twice weekly for 30 weeks. At the 12, 4 and 1.33 nmol doses, anti-DB[a,l]PDE induced 2.0, 0.7 and 0.7 tumors per mouse (t/m) respectively, whereas syn DB[a,l]PDE induced 1.8, 1.5 and 1.8 t/m. At the same three doses, DB[a,l]P-11,12-dihydrodiol induced 4.6, 4.3 and 2.8 t/m, and DB[a,l]P resulted in 9.3,7.1 and 5.2 t/m. These results confirm that DB[a,l]P is more potent than its 11,12-dihydrodlol and show that the two diolepoxides are less tumorlgenic than their precursors. At the medium and low doses, syn-DB[a,l]PDE is more tumorigenic than its congener anti-DB[a,l]PDE.
UR - http://www.scopus.com/inward/record.url?scp=0027959934&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027959934&partnerID=8YFLogxK
U2 - 10.1093/carcin/15.11.2455
DO - 10.1093/carcin/15.11.2455
M3 - Article
C2 - 7955091
AN - SCOPUS:0027959934
SN - 0143-3334
VL - 15
SP - 2455
EP - 2460
JO - Carcinogenesis
JF - Carcinogenesis
IS - 11
ER -